Valerie Vanhooren

Valerie Vanhooren is the Co-founder and CEO of ONA Therapeutics, a biotechnology company focused on developing novel biotherapeutics for advanced cancers.12 She has extensive experience in the biotech industry and a strong background in scientific research.

Professional Background

Valerie's career trajectory includes:

Leadership Roles::

• Co-founder & CEO at ONA Therapeutics since May 20191
• Director of R&D at ProteoDesign (November 2018 - April 2019)
• Project Leader at ProteoDesign (December 2017 - November 2018)

Previous Experience::

• Business Development and Project Manager at Intelligent Pharma
• Project Leader/Planner at Ablynx
• Postdoctoral Researcher at VIB and IRB Barcelona

Education and Expertise

Valerie holds a Ph.D. from Ghent University, where she was a Ph.D. student from January 2006 to December 2009.1 Her academic background, combined with her industry experience, has equipped her with a unique blend of scientific knowledge and business acumen.

Role at ONA Therapeutics

As the Co-founder and CEO of ONA Therapeutics, Valerie has been instrumental in guiding the company's growth and development since its founding in 2019.23 Under her leadership, ONA Therapeutics has:

• Focused on developing antibody-drug conjugates (ADCs) and monoclonal antibodies for cancer treatment
• Maintained two wholly owned internal programs, including a lead program for an undisclosed first-in-class ADC targeting refractory breast cancer
• Assembled a multinational team of experienced biotech executives

Skills and Languages

Valerie is multilingual, with proficiency in Spanish, French, Dutch, and English.1 Her diverse skill set includes project management, business development, and scientific research, making her well-suited to lead a cutting-edge biotech company.